Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2016; 15(03): 173-178
DOI: 10.4103/1450-1147.174703
Original article

Gastrointestinal side effects of the radioiodine therapy for the patients with differentiated thyroid carcinoma two days after prescription

Mehran Pashnehsaz
1   Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, Iran
,
Abbas Takavar
1   Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, Iran
2   Department of Nuclear Medicine, Research Institute for Nuclear Medicine, Shariati Hospital, Tehran
,
Sina Izadyar
3   Department of Nuclear Medicine, Tehran University of Medical Sciences, Tehran
,
Seyed Zakariaee
1   Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, Iran
,
Mahmoud Mahmoudi
4   Department of Statistical in Medicine, Tehran University of Medical Sciences, Tehran
,
Reza Paydar
5   Department of Radiation Sciences, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran
,
Parham Geramifar
2   Department of Nuclear Medicine, Research Institute for Nuclear Medicine, Shariati Hospital, Tehran
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Iodine-131 (I-131) therapy is one of the conventional approaches in the treatment of patients with differentiated thyroid carcinoma (DTC). The radioiodine agents also accumulate in the other organs that cause pain and damage to the patients. Radioiodine therapy is associated with various gastrointestinal (GI) toxicities. In this study, GI side effects of the radioiodine therapy were investigated. GI toxicities of the radioiodine therapy were studied in 137 patients with histologically proven DTC in Jun-Nov 2014. All the patients were treated by radioiodine agents in the research institute of Shariati Hospital, Tehran, Iran. The patients were examined 48 h after prescription (before discharge) and their GI side effects were registered. Correlation of the age, gender, administered dose, administered dose per body weight as the independent factors, and GI side effects were analyzed using the Pearson correlation test with Statistical Package for the Social Sciences (SPSS) version 20. Regression coefficients and linearity of the variable were investigated by MATLAB software. Line fitting was performed using MATLAB curve-fitting toolbox. From the subjects, 38 patients had GI complaints (30.4%). Significant factors influencing GI side effects were dose per body weight and administered doses. There was no significant correlation between age and gender as the independent parameters and GI complaints. The most prevalent GI side effect was nausea that occurs in 26.4% of the patients. From the results, it could be concluded that the GI side effects could be prevented by administering a safe radioiodine dose value less than 5,550 MBq.

Keywords

Gastrointestinal (GI) side effects - radioiodine therapy - short-term side effects - thyroid cancer


Publication History

Article published online:
19 May 2022

© 2016. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India